Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Immunovant (IMVT) Return on Invested Capital (2019 - 2026)

Immunovant filings provide 7 years of Return on Invested Capital readings, the most recent being 0.01% for Q4 2025.

  • Quarterly Return on Invested Capital changed 0.0% to 0.01% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.01% through Dec 2025, changed 0.0% year-over-year, with the annual reading at 0.01% for FY2025, 0.0% changed from the prior year.
  • Return on Invested Capital hit 0.01% in Q4 2025 for Immunovant, up from 0.01% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.0% in Q4 2021 and bottomed at 0.01% in Q4 2024.
  • Average Return on Invested Capital over 5 years is 0.01%, with a median of 0.01% recorded in 2023.
  • The largest annual shift saw Return on Invested Capital changed 0bps in 2021 before it dropped -1bps in 2023.
  • Immunovant's Return on Invested Capital stood at 0.0% in 2021, then crashed by -85bps to 0.0% in 2022, then dropped by -7bps to 0.01% in 2023, then tumbled by -83bps to 0.01% in 2024, then skyrocketed by 35bps to 0.01% in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Return on Invested Capital are 0.01% (Q4 2025), 0.01% (Q3 2025), and 0.01% (Q2 2025).